The Mentor with Mark Bouris

Mark Bouris speaks to business owners and entrepreneurs, finding out what makes them tick and their plans for growth. Some business owners are on the way up and enjoying new success, others are at a turning point. Mark digs into their stories and finds out why they set out to create their own path, their challenges and where they go from here. Based on his own personal experiences and learnings, he also passes on his own guidance on how to take their business to the next level. Hosted on Acast. See acast.com/privacy for more information.

https://mentored.com.au/homepage/shows/the-mentor/

subscribe
share






The Next Wave of Antibiotic resistance: Going Public w James Graham


With Stake, Australia's leading investing platform, I'm excited to share the eighth episode of 'Going Public' - a new monthly series giving you unique access to the entrepreneurs, founders and executives who've taken their business public.


This podcast will delve into the journey of James Graham, one of the youngest CEOs in Australia's public company sector. At 36, James leads Recce Pharmaceuticals (ASX:RCE) , a rapidly growing medical technology firm taking on antibiotic resistance, a global health crisis.


We explore the highs and lows of building a biotech company, the road to going public, and the impact of Recce's novel approach to fighting infectious diseases. Get insights into James' journey from startup entrepreneur to industry leader, his perspectives on global health, and his vision for making a lasting impact.


In 2016, Recce was listed on the Australian Securities Exchange with the stock ticker RCE.



DISCLAIMER:

Views expressed are those of the individual only. This does not constitute financial advice. 

You can subscribe to the newsletter here: https://lnkd.in/e7C8akgj. 

Join the Facebook Group.

Follow Mark Bouris on InstagramLinkedIn YouTube

See omnystudio.com/listener for privacy information.


Hosted on Acast. See acast.com/privacy for more information.


fyyd: Podcast Search Engine
share








   37m